Krishnansu S Tewari

18PUBLICATIONS
106CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Diagnostic radiography
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 01, 2025
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.

Yong-Man Kim, Shin Nishio, Se Ik Kim

|Dec 19, 2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.

Daniela E Matei, Danielle M Enserro, Marcus E Randall

|Oct 25, 2024
Erratum: Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.

Eduardo García, Natalie Ayoub, Krishnansu S Tewari

|Dec 10, 2023
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.

Eduardo García, Natalie Ayoub, Krishnansu S Tewari

|Nov 01, 2023
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.

Bradley J Monk, Nicoletta Colombo, Krishnansu S Tewari

|Oct 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer

Pageof 3

Frequent Collaborators

7 joint publications

Bradley J Monk

4 joint publications

David Mutch

4 joint publications

Domenica Lorusso

3 joint publications

David S Miller